Abstract

ObjectiveTo investigate the prevalence and distribution of cervical lymph node metastasis (LNM) in locally advanced supraglottic squamous cell carcinoma (LASCC) and guide the delineation of clinical lymph node target volumes.Materials and MethodsWe reviewed patients defined as LASCC from January 2000 to December 2017 in our hospital. The primary tumor was operated on using partial or total laryngectomy, and all patients underwent bilateral neck dissection (levels II–IV at least). Univariate and multivariate logistic regressions were used to find risk factors associated with LNM.ResultsA total of 206 patients were enrolled. In the whole group, the rate of ipsilateral metastasis (IM) was 60.9% (67 patients), whereas contralateral metastasis was 25.5% (28 patients). Only positive ipsilateral lymph nodes contributed to contralateral metastasis (p = 0.001). Seventy-six cases were diagnosed with clinical positive lymph nodes (cN+). IM of primary lesions mainly located within the unilateral sites (n = 49 patients) was detected in levels II, III, and IV with lymph node metastasis ratios of 73.5% (36 patients), 63.3% (31 patients), and 20.4% (10 patients), respectively, and contralateral metastasis of 36.7% (18 patients), 16.3% (8 patients), and 6.1% (3 patients), respectively. Involvement of level II or III was associated with metastasis of level IV. No one developed contralateral level IV involvement without metastasis of contralateral levels II and III. A total of 130 cases had clinically negative neck lymph nodes (cN0). The prevalence of occult metastasis (OM) was 35.4%. Among 62 patients with unilateral lesions, the rates of OM to ipsilateral neck levels II, III, and IV were 21, 11.1, and 1.6%, respectively, whereas contralateral neck levels were 6.3, 4.8, and 0%, respectively. In terms of the risk factors, histopathological differentiation was related to OM (p = 0.003). Two of 25 people were with level VIb metastasis, and both of them were with subglottic involvement.ConclusionNeck levels II to IV are most frequently involved and should be included in clinical target volume (CTV) in cN+ patients. Contralateral IV may be omitted when contralateral levels II and III are negative. In cN0 patients, ipsilateral levels II and III are suggested to be included in the CTV, whereas whether contralateral levels II and III should be included needs further research.

Highlights

  • Laryngeal cancer still ranks high in incidence rate among the upper aerodigestive tract (1), and 85–95% of these cancers are squamous cell carcinomas (2)

  • Metastasis was detected in levels II, III, and IV with LNM ratios (LMRs) of 23.8% (31), 22.3% (29), and 2.3% (3)

  • Sixty (78.9%) and 48 (63.2%) patients had level II or III metastasis in cN+ group, so we focused on the risk factors associated with lymph node metastasis (LNM) in level IV

Read more

Summary

Introduction

Laryngeal cancer still ranks high in incidence rate among the upper aerodigestive tract (1), and 85–95% of these cancers are squamous cell carcinomas (2). For most patients with T3 or T4 disease without tumor invasion through cartilage into soft tissues, concurrent chemoradiotherapy is an appropriate approach (9). The detailed lymph node regions that should be included in clinical target volumes (CTV) are still controversial (10, 11), especially level IV and contralateral lymph node levels in patients with cN0. Guidelines for radiotherapy in Danish Head and Neck Cancer Group (DAHANCA) suggest that bilateral levels II and III should be included in CTV in cN0 patients of locally advanced supraglottic squamous cell carcinoma (LASCC) (12), whereas in international consensus bilateral level IV is advised (10). Most guidelines do not take risk factors of lymph node metastasis (LNM), such as T stage, histopathological differentiation, tumor subsite, and so on, into consideration for selection and delineation of lymphatic CTVs. We designed this study to investigate the patterns and risk factors of cervical LNM in LASCC to help guide individualized delineation of neck CTV for radical radiotherapy

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call